(Q41104253)
Statements
1 reference
A phase 1, randomized, dose-ranging study of GS-5816, a once-daily NS5A inhibitor, in patients with genotype 1-4 hepatitis C virus (English)
1 reference
E Lawitz
1 reference
B Freilich
1 reference
J Link
1 reference
P German
1 reference
H Mo
1 reference
L Han
1 reference
D M Brainard
1 reference
J McNally
1 reference
T Marbury
1 reference
M Rodriguez-Torres
1 reference
16 July 2015
1 reference
1 reference
1011-1019
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
Identifiers
1 reference